A U.S. Patent Application for “End to End Cell Therapy Automation” was published by Lonza on March 5th, 2020. The present invention is a method for automated production of a genetically modified immune cell culture, the method performed by a cell engineering system, comprising: (a) activating an immune cell culture with an activation reagent to produce an activated immune cell culture in a first chamber of the cell engineering system; (b) transducing the activated immune cell culture, the transducing comprising: i. transferring via a first sterile, closed connection, the activated immune cell culture from the first chamber to an electroporation unit… Learn More